Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Group To Intensify Health Care Investment In China

This article was originally published in PharmAsia News

Executive Summary

Bayer Group China recently revealed that the group will increase investment for its three business sectors-m aterial science, health care and crop science-over the next few years. The proportion of allocation will depend on the market development strategy under preparation and upcoming policies in China. The group will step up efforts in health care while it will slow down the pace for material science, currently its largest and most established sector in China. Besides importing technology, Bayer's health care in China will actively look for acquisitions or mergers, and expand funding in drug labs and clinical trials. In addition, the firm plans to launch about 20 medicines in China within the next five years. (Click here for more - Chinese Language)

You may also be interested in...



Asia Executives On The Move: Sanofi's Global R&D Head Moves To Innovent

Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.

Woodcock's Prophesy Comes True: US FDA ANDA Approvals Decline From Record Levels

Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.

Endo Brings All Xiaflex Revenue In House With BioSpecifics Acquisition

Deal snapshot: Resolving a loose end from its 2014 buyout of Auxilium, Endo acquires all rights to Xiaflex, along with approved cellulite therapy Qwo.

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel